Tirzepatide vs Semaglutide: The Complete Comparison Guide

Both tirzepatide and semaglutide are highly effective for weight loss. Tirzepatide tends to produce greater average weight loss in clinical trials (~21% vs ~15% over a year), and many patients tolerate it slightly better. Semaglutide has a longer track record, more real-world data, and more available manufacturer programs.

The right choice depends on your insurance coverage, your goals, your tolerance for side effects, your medical history, and how your body responds. There's no universally “better” option — only the better option for you.

Read on for the detailed comparison: mechanism, side effects, results, cost, and brand differences (Mounjaro vs Zepbound, Wegovy vs Ozempic).

Both medications belong to a class called incretin mimetics — they mimic gut hormones that signal satiety to the brain. But they target different receptors:

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain (reducing appetite), the pancreas (improving insulin response), and the GI tract (slowing gastric emptying so you feel full longer).

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual action appears to enhance the metabolic and weight loss effects beyond what GLP-1 activation alone produces.

This dual mechanism is why tirzepatide tends to outperform semaglutide in head-to-head trials — but it also means tirzepatide can produce more pronounced GI effects in some patients.

This is where things get confusing. The same medication sometimes has two brand names depending on what it's FDA-approved for:

Tirzepatide:

• Mounjaro — FDA-approved for type 2 diabetes

• Zepbound — FDA-approved for chronic weight management

Both are manufactured by Eli Lilly. The active ingredient and dosing are identical. The difference is which condition the manufacturer studied for FDA approval and how the drug is labeled.

Semaglutide:

• Ozempic — FDA-approved for type 2 diabetes

• Wegovy — FDA-approved for chronic weight management

• Rybelsus — oral tablet form for type 2 diabetes (not commonly used for weight loss)

Ozempic and Wegovy are both manufactured by Novo Nordisk and contain the same active ingredient (semaglutide), but Wegovy is dosed slightly higher than Ozempic for weight loss purposes.

Insurance coverage often depends on which brand you're prescribed and which condition is being treated. Patients with type 2 diabetes typically have better coverage for Mounjaro/Ozempic; patients without diabetes often need Zepbound/Wegovy and may face more coverage hurdles.

The major head-to-head data we have:

Semaglutide (STEP 1 trial, 2021) — Patients on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% on placebo.

Tirzepatide (SURMOUNT-1 trial, 2022) — Patients on tirzepatide 15 mg weekly lost an average of 22.5% of body weight over 72 weeks. The 10 mg dose produced 19.5% loss; the 5 mg dose produced 15% loss.

Direct comparison (SURMOUNT-5, 2025) — In a head-to-head trial of tirzepatide vs semaglutide for weight loss, tirzepatide produced 20.2% body weight loss versus semaglutide's 13.7% over 72 weeks — roughly 47% greater weight loss with tirzepatide.

Real-world results vary based on starting weight, dose, adherence, lifestyle factors, and individual response. About 80–90% of patients on either medication achieve clinically meaningful weight loss (≥5%); a smaller subset doesn't respond well to either.

Importantly, weight loss is typically maintained as long as the medication is continued. Stopping either medication often results in weight regain unless lifestyle changes have become firmly established.

Both medications share a similar GI-focused side effect profile, particularly during dose escalation:

Most common (both medications):

• Nausea (most common, typically mild-to-moderate, often improves over time)

• Vomiting

• Diarrhea or constipation

• Reduced appetite (this is the goal but can become uncomfortable)

• Fatigue during dose increases

Several head-to-head studies suggest tirzepatide may produce slightly milder GI side effects on average, though individual responses vary substantially.

Less common but reported with both:

• Hair loss (typically temporary, related to rapid weight loss rather than the medication itself)

• Fatigue (some patients report this; for others, energy improves with weight loss)

• Gallbladder issues (rare but documented)

• Pancreatitis (rare; both medications carry warnings)

Both medications carry FDA warnings about thyroid C-cell tumors based on rodent studies, though human risk is not established. Patients with personal or family history of medullary thyroid cancer or MEN2 syndrome should not use either medication.

Both medications use a slow dose-escalation schedule to minimize side effects, so initial results take time:

Semaglutide — Most patients begin at 0.25 mg weekly and increase every 4 weeks to 0.5, 1.0, 1.7, and finally 2.4 mg. Meaningful weight loss typically begins after 4–8 weeks; significant results appear at 3–6 months.

Tirzepatide — Most patients begin at 2.5 mg weekly and increase every 4 weeks to 5, 7.5, 10, 12.5, and finally 15 mg. Similar timeline — results begin in the first 4–8 weeks, accelerate over the first 6 months, and continue to develop through the first year.

Both medications work best when continued long enough to reach effective doses. Stopping early because of slow initial results is one of the most common reasons treatment fails.

Cost is a major factor for most patients. Without insurance coverage:

• Wegovy (semaglutide for weight loss) — typically $1,300–1,400 per month list price

• Zepbound (tirzepatide for weight loss) — typically $1,000–1,100 per month list price

• Ozempic / Mounjaro (when prescribed for diabetes with coverage) — frequently $25–100 per month with insurance

Manufacturer savings programs can dramatically reduce these prices for eligible patients. Eli Lilly offers a Zepbound savings card; Novo Nordisk offers a similar Wegovy program. The single-vial pricing programs (like Lilly's $349/month direct-purchase Zepbound vials) have made tirzepatide significantly more accessible.

Compounded versions of semaglutide and tirzepatide were widely used during FDA shortages, but most have been phased out as the brand-name medications became consistently available. Compounded versions are not FDA-approved and quality varies significantly between sources.

Insurance coverage is shifting rapidly. Some employer plans cover GLP-1s for weight loss; many do not. Medicare typically does not cover GLP-1s for weight loss (though that may change). Our Fort Collins team can help you navigate coverage and savings programs to figure out which option is most affordable for your situation.

Liraglutide (Saxenda for weight loss, Victoza for diabetes) was the first GLP-1 widely used for weight management. It's a daily injection (rather than weekly) and produces less weight loss than semaglutide or tirzepatide — typically 5–8% body weight loss over a year.

For most patients today, semaglutide or tirzepatide is preferred over liraglutide given:

• Greater weight loss

• Weekly dosing instead of daily

• Comparable or milder side effect profile

Liraglutide may still be appropriate for patients with insurance coverage limitations, those who can't access weekly GLP-1s, or those who tolerate daily dosing better.

Retatrutide is an investigational triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, retatrutide produced 24% body weight loss over 48 weeks, the highest of any weight loss medication tested to date.

Retatrutide is not yet FDA-approved and remains in clinical development as of late 2026. Phase 3 trials are ongoing, and approval is anticipated within the next 1–2 years if results continue to look favorable.

For now, tirzepatide represents the most effective FDA-approved option, with retatrutide on the horizon as the likely next step.

There's no universal answer — the right choice depends on:

• Your insurance coverage (which is often the deciding factor)

• How your body tolerates each medication

• Whether you have type 2 diabetes (affecting which brand and coverage path)

• Your weight loss goals (modest vs significant)

• Your preference for convenience, cost, or maximum efficacy

Tirzepatide is often preferred when maximum weight loss is the priority and access/cost isn't the limiting factor. Semaglutide is often the right choice when insurance coverage is better, when patients want a longer track record, or when GI side effects from tirzepatide are problematic.

Many patients also do well switching between medications based on response, tolerability, and access. The best decision involves a real conversation with a provider who knows your medical history and goals.